« Return to News | CROs/Service Providers

CenterWatch Commentary: More Bad News for Encorium

Friday, September 26, 2008 01:25 PM

If this week’s news is any indication, Encorium’s summer of ups and downs will continue into fall.

The Wayne, Pa.-based contract research organization (CRO) is reducing its staff by 18%, effective immediately, and postponing negotiations to acquire Prologue Research, a Columbus, Ohio-based CRO specializing in oncology. This news comes just days after Encorium’s shares fell almost 50% following the company’s announcement that it had terminated plans to purchase Fine Success Investments, a holding company doing business as Linkcon. In an investor conference call earlier this month, Encorium executives cited the Prologue acquisition, expected to close Sept. 19, as a key to the company’s future financial success. This week, the deal is off.

On the up side, the recent cost-cutting initiatives are expected to save the company approximately $1 million annually, enabling them to focus on business development and organic growth, according to Encorium’s new CEO David Ginsberg. Ginsberg is optimistic about the company’s future and even announced $6.2 million in new business contracts with “major pharmaceutical companies.”

But, with bad news for this company coming more often than good (and a stock price that remains stuck around $0.35), it seems less likely that this CRO’s story will have a happy ending.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.